美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Evommune

22.98

+1.969.32%

成交量：34.01萬

成交額：785.49萬

市值：8.28億

市盈率：-10.52

高：24.14

開：21.50

低：21.24

收：21.02

52周最高：33.20

52周最低：13.89

股本：3,601.84萬

流通股本：937.50萬

量比：0.76

換手率：3.63%

股息：- -

股息率：- -

每股收益(TTM):-2.1850

每股收益(LYR):-11.2228

淨資產收益率：-54.42%

總資產收益率：-33.67%

市淨率：4.03

市盈率(LYR):-2.05

資料載入中...

總覽公司新聞資訊公告

Evommune, Inc.盤中異動快速下跌6.16%

Evommune, Inc.盤中異動快速下跌5.11%報25.27美元

Evommune, Inc.盤中異動急速下跌5.23%

Evommune, Inc.盤中異動大幅跳水5.09%報27.01美元

BUZZ-濕疹療法在中期試驗中表現良好，Evommune業績大漲

Evommune公司：同時評估Evo301的潛在新增適應症，包括潰瘍性結腸炎

Evommune公布Evo301治療中重度特應性皮炎二期a期概念驗證試驗積極頂線數據

Aktis Oncology申請美國IPO，生物技術公司上市反彈

實時市場-標普 500 指數迎來 2024 年第四季度以來最大利潤增長季

實時市場-斯蒂芬斯調整 2026 年羅素重組的觀點

Evommune首次公開募股定價為每股16美元，發行937.5萬股

BUZZ-Evommune 首次公開募股募集 1.5 億美元，在紐交所首次亮相即大漲

美股異動 | 生物醫藥公司Evommune(EVMN.US)登陸美股市場股價升逾15%

慢性炎症性疾病生物科技公司Evommune(EVMN.US)IPO定價15-17美元/股擬籌資1.5億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/EVMN/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EVMN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","market":"US","secType":"STK","nameCN":"Evommune","latestPrice":22.98,"timestamp":1774466903314,"preClose":21.02,"halted":0,"volume":340125,"delay":0,"changeRate":0.09324452901998101,"floatShares":9375000,"shares":36018400,"eps":-2.185,"marketStatus":"交易中","change":1.96,"latestTime":"03-25 15:28:44 EDT","open":21.5001,"high":24.14,"low":21.24,"amount":7854853.212375,"amplitude":0.137964,"askPrice":23.05,"askSize":39,"bidPrice":22.91,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.185,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774468800000},"marketStatusCode":2,"adr":0,"listingDate":1762405200000,"exchange":"NYSE","adjPreClose":21.02,"preHourTrading":{"tag":"盘前","latestPrice":21.53,"preClose":21.02,"latestTime":"09:27 EDT","volume":1478,"amount":32225.80948,"timestamp":1774445242229,"change":0.51,"changeRate":0.024263,"amplitude":0.033777},"postHourTrading":{"tag":"盘后","latestPrice":21.13,"preClose":21.02,"latestTime":"19:59 EDT","volume":11383,"amount":243518.5934,"timestamp":1774396786502,"change":0.11,"changeRate":0.005233,"amplitude":0.033016},"volumeRatio":0.758164},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EVMN\",,,,,undefined,":{"symbol":"EVMN","floatShares":9375000,"roa":"-33.67%","roe":"-54.42%","lyrEps":-11.222761,"volumeRatio":0.758164,"shares":36018400,"dividePrice":0,"high":24.14,"amplitude":0.137964,"preClose":21.02,"low":21.24,"week52Low":13.885,"pbRate":"4.03","psRate":"63.67","week52High":33.2,"institutionHeld":0,"latestPrice":22.98,"committee":0.67364,"eps":-2.185,"divideRate":0,"volume":340125,"delay":0,"ttmEps":-2.185,"open":21.5001,"prevYearClose":17.12,"prevWeekClose":23.33,"prevMonthClose":26,"prevQuarterClose":17.12,"fiveDayClose":24.09,"twentyDayClose":29.86,"sixtyDayClose":17.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EVMN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-05","symbol":"EVMN","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"盤後","type":"earning","dateTimestamp":1772686800000,"reportTimeType":"post","actualEps":-1.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EVMN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EVMN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4444,"buy":0.5556,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1773201600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EVMN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EVMN","date":"2026-03-24","current":-9.942792,"percent":0.229167,"low":-16.229076,"twenty":-12.350949,"median":-9.657505,"eighty":-8.713066,"high":-7.430686,"avg":-10.452926,"sd":2.237312,"marketCap":844630823},"quantilePoints":[{"date":"2025-11-07","current":-9.395174,"twenty":-7.823584,"median":-7.430686,"eighty":-7.430686,"marketCap":608469038},{"date":"2025-11-14","current":-8.461694,"twenty":-9.04686,"median":-8.505813,"eighty":-7.430686,"marketCap":548013143},{"date":"2025-11-21","current":-8.689259,"twenty":-9.04686,"median":-8.689259,"eighty":-7.430686,"marketCap":562751147},{"date":"2025-11-28","current":-9.618094,"twenty":-9.051504,"median":-8.707835,"eighty":-8.049291,"marketCap":622906267},{"date":"2025-12-05","current":-10.184684,"twenty":-9.618094,"median":-8.986487,"eighty":-8.483986,"marketCap":659600890},{"date":"2025-12-12","current":-9.657505,"twenty":-9.633858,"median":-9.000419,"eighty":-8.483986,"marketCap":592227156},{"date":"2025-12-19","current":-7.716136,"twenty":-9.618094,"median":-8.986487,"eighty":-8.244704,"marketCap":473176635},{"date":"2025-12-26","current":-9.042428,"twenty":-9.528926,"median":-9.016673,"eighty":-8.355807,"marketCap":554508795},{"date":"2026-01-02","current":-8.800817,"twenty":-9.392482,"median":-9.003431,"eighty":-8.469125,"marketCap":539692472},{"date":"2026-01-09","current":-9.37143,"twenty":-9.380689,"median":-8.972554,"eighty":-8.293747,"marketCap":574684215},{"date":"2026-01-16","current":-10.075701,"twenty":-9.649623,"median":-9.019686,"eighty":-8.354639,"marketCap":617872222},{"date":"2026-01-23","current":-9.710714,"twenty":-9.690151,"median":-9.037572,"eighty":-8.461694,"marketCap":595490116},{"date":"2026-01-30","current":-11.129537,"twenty":-9.775997,"median":-9.042428,"eighty":-8.498847,"marketCap":682496613},{"date":"2026-02-06","current":-8.564346,"twenty":-9.775997,"median":-9.064213,"eighty":-8.549933,"marketCap":525191389},{"date":"2026-02-13","current":-14.332171,"twenty":-9.885497,"median":-9.065437,"eighty":-8.563866,"marketCap":878891712},{"date":"2026-02-20","current":-14.769127,"twenty":-10.094711,"median":-9.253195,"eighty":-8.56425,"marketCap":905687191},{"date":"2026-02-27","current":-13.689588,"twenty":-10.579486,"median":-9.338016,"eighty":-8.621921,"marketCap":839486596},{"date":"2026-03-06","current":-11.484529,"twenty":-11.200535,"median":-9.381712,"eighty":-8.67867,"marketCap":790939493},{"date":"2026-03-13","current":-12.018327,"twenty":-12.245567,"median":-9.479385,"eighty":-8.689259,"marketCap":827702188},{"date":"2026-03-20","current":-12.321662,"twenty":-12.396972,"median":-9.618094,"eighty":-8.70412,"marketCap":848592844},{"date":"2026-03-24","current":-12.264133,"twenty":-12.350949,"median":-9.657505,"eighty":-8.713066,"marketCap":844630823}],"updateTime":1774445707857},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EVMN\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2617590756","title":"Evommune, Inc.盤中異動 快速下跌6.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617590756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617590756?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 22:41","pubTimestamp":1772635288,"startTime":"0","endTime":"0","summary":"北京时间2026年03月04日22时41分，Evommune, Inc.股票出现异动，股价大幅下挫6.16%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Klotho Neurosciences Inc C/Wts 21/06/2029 、Klotho Neurosciences, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 涨幅较大，Klotho Neurosciences, Inc.、Onconetix, Inc.、Edesa Biotech, Inc.较为活跃，换手率分别为38.04%、31.92%、23.82%，振幅较大的相关个股有Klotho Neurosciences, Inc.、Edesa Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为28.39%、20.67%、13.00%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304224128a6a29a01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304224128a6a29a01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2614897402","title":"Evommune, Inc.盤中異動 快速下跌5.11%報25.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614897402","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614897402?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 22:48","pubTimestamp":1772203739,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日22时48分，Evommune, Inc.股票出现波动，股价急速下跌5.11%。截至发稿，该股报25.27美元/股，成交量6.4999万股，换手率0.21%，振幅8.30%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227224859a7274650&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227224859a7274650&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2612019442","title":"Evommune, Inc.盤中異動 急速下跌5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612019442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612019442?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 03:28","pubTimestamp":1771356532,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日03时28分，Evommune, Inc.股票出现异动，股价快速跳水5.23%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Polaryx Therapeutics, Inc.、Cibus, Inc.、Biodexa Pharmaceuticals Plc涨幅较大，Ensysce Biosciences, Inc.、Polaryx Therapeutics, Inc.、Ernexa Therapeutics Inc.较为活跃，换手率分别为810.90%、101.69%、96.36%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Ensysce Biosciences, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为81.33%、74.28%、39.89%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218032852a4ae1699&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218032852a4ae1699&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"2611901796","title":"Evommune, Inc.盤中異動 大幅跳水5.09%報27.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611901796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611901796?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 22:32","pubTimestamp":1770906774,"startTime":"0","endTime":"0","summary":"北京时间2026年02月12日22时32分，Evommune, Inc.股票出现波动，股价快速跳水5.09%。截至发稿，该股报27.01美元/股，成交量2.4506万股，换手率0.08%，振幅2.16%。Evommune, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Evommune, Inc.公司简介：Evommune Inc 是一家临床阶段的生物技术公司，专注于开发针对慢性炎症性疾病关键驱动因素的新型疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212223254a49ce8d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2610062539","title":"BUZZ-濕疹療法在中期試驗中表現良好，Evommune業績大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2610062539","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610062539?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 21:52","pubTimestamp":1770731563,"startTime":"0","endTime":"0","summary":"BUZZ-湿疹疗法在中期试验中表现良好，Evommune业绩大涨2月10日 - ** 药物开发商Evommune EVMN.N 股价盘前大涨102.47%，至33.8美元 ** 该公司称  其试验性疗法 EVO301 在中重度特应性皮炎患者中的测试达到了中期试验的主要目标。** 特应性皮炎或湿疹是一种慢性皮肤病，由于皮肤屏障缺陷和过度活跃的免疫反应，会导致皮肤干燥、发痒、发炎。** 在一项有 70 名患者参加的试验中，与服用安慰剂的患者相比，服用 EVO301 的患者中有 23% 的人皮肤状况清晰或接近清晰，并有明显改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nL4T3Z61KD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN","BK4139"],"gpt_icon":0},{"id":"1168920254","title":"Evommune公司：同時評估Evo301的潛在新增適應症，包括潰瘍性結腸炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1168920254","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168920254?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 20:32","pubTimestamp":1770726755,"startTime":"0","endTime":"0","summary":"Evommune公司正在对Evo301的潜在新增适应症展开评估，其中溃疡性结肠炎是重点考察方向之一。这一举措旨在拓宽该药物的应用范围，为更多患者提供治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"1100113507","title":"Evommune公布Evo301治療中重度特應性皮炎二期a期概念驗證試驗積極頂線數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1100113507","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100113507?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 20:31","pubTimestamp":1770726682,"startTime":"0","endTime":"0","summary":"生物制药公司Evommune近日宣布，其研发的候选药物Evo301在中重度特应性皮炎患者中开展的二期a期概念验证试验获得积极顶线结果。\n该试验数据表明Evo301在主要疗效终点上表现出显著改善，验证了其治疗潜力。这项突破为后续临床开发奠定了坚实基础，有望为特应性皮炎患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EVMN"],"gpt_icon":0},{"id":"2592118027","title":"Aktis Oncology申請美國IPO，生物技術公司上市反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=2592118027","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592118027?lang=zh_tw&edition=fundamental","pubTime":"2025-12-20 06:45","pubTimestamp":1766184351,"startTime":"0","endTime":"0","summary":"Aktis Oncology申请美国IPO，生物技术公司上市反弹路透12月19日 - Aktis Oncology公司周五在美国提交了首次公开募股申请，生物技术行业的股市上市在经历了放缓后出现反弹。Aktis Oncology 公司由生物技术投资者托德-福里于 2020 年 8 月共同创立，目前正在开发治疗多种实体瘤的药物。Aktis Oncology 的主要候选药物 AKY-1189 正在进行早期研究，以治疗某些实体瘤，包括一种晚期膀胱癌、乳腺癌和结直肠癌。Aktis Oncology 公司的前身是 HotKnot Therapeutics 公司，将在纳斯达克上市，股票代码为 \"AKTS\"。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL4T3XP1JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","LBRX","LU0256863811.USD","LU0648001328.SGD","LU1069347547.HKD","LU0130102774.USD","LU0208291251.USD","LU0310800965.SGD","LU0306806265.USD","LU2129689431.USD","LU0130517989.USD","IE00BLSP4452.SGD","LU1074936037.SGD","LU0256863902.USD","LU0320765489.SGD","MPLT","OWL","LU1880398554.USD","LU0052756011.USD","LU0477156797.USD","LU1883839398.USD","LU1035773651.USD","BK4553","LU0980610538.SGD","LU2129689514.USD","LU0203347892.USD","BK4585","IE00BZ1G4Q59.USD","LU1791807156.HKD","LU1804176565.USD","LU1363072403.SGD","LU0130103400.USD","IE0034235188.USD","LU1201861165.SGD","LU1668664300.SGD","IE0001KFT4U8.USD","BAC","EVMN","LU0128525689.USD","LU0648000940.SGD","LU1162221912.USD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU0234572021.USD","LU0321505439.SGD","LU1894683348.USD","BK4534","MNSH","LU0306807586.USD","LU1201861249.SGD"],"gpt_icon":0},{"id":"2591062657","title":"實時市場-標普 500 指數迎來 2024 年第四季度以來最大利潤增長季","url":"https://stock-news.laohu8.com/highlight/detail?id=2591062657","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591062657?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 02:30","pubTimestamp":1765823402,"startTime":"0","endTime":"0","summary":"12月15日 - 欢迎访问路透记者为您提供的市场实时报导主页。根据 LSEG 的数据，随着本季度的结束，标普 500.SPX公司第三季度的盈利增长达到 15%，这是自 2024 年第四季度的 17.1%以来最大的同比增长。标普 500 指数第四季度的盈利增长率为 8.5%，迄今为止，负面展望与正面展望相比，数量低于长期和近期平均水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4T3XL1C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4187","PURR","CBC","CDNL","LMRI","BETA","XZO","EVMN","BK4139"],"gpt_icon":0},{"id":"2591625691","title":"實時市場-斯蒂芬斯調整 2026 年羅素重組的觀點","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625691","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591625691?lang=zh_tw&edition=fundamental","pubTime":"2025-12-16 01:35","pubTimestamp":1765820127,"startTime":"0","endTime":"0","summary":"实时市场-斯蒂芬斯调整 2026 年罗素重组的观点美国主要股指小幅下跌，纳斯达克指数下跌 ~0.4医疗保健板块领涨；能源板块走势最弱欧元 STOXX 600 指数上涨 ~0.7美元下跌；原油下跌 >1%，比特币下跌 ~3%；黄金 ~持平美国 10 年期国债收益率跌至 ~4.18. 罗伯茨还预计将增加 7 家 IPO，其中 1 家进入罗素 1000 指数，6 家进入小盘股指数。罗素按季度增加 IPO，在 11 月 1 日至 2026 年 1 月 31 日期间定价和交易的 IPO 有资格纳入 2026 年第一季度，并在 3 月 20 日收盘后加入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nL4T3XL19Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PURR","EVMN","BK4187","BK4107","CBC","BETA","CDNL","BK4211","LMRI","XZO","HCI"],"gpt_icon":0},{"id":"1101351099","title":"Evommune首次公開募股定價為每股16美元，發行937.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101351099","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101351099?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 00:46","pubTimestamp":1763570777,"startTime":"0","endTime":"0","summary":"11月5日 - Evommune Inc 公告：*Evommune宣布首次公开募股定价* Evommune Inc - 首次公开募股定价为每股16美元，共发行937.5万股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"gpt_icon":0},{"id":"2581011513","title":"BUZZ-Evommune 首次公開募股募集 1.5 億美元，在紐交所首次亮相即大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2581011513","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581011513?lang=zh_tw&edition=fundamental","pubTime":"2025-11-07 03:06","pubTimestamp":1762455984,"startTime":"0","endTime":"0","summary":"BUZZ-Evommune 首次公开募股募集 1.5 亿美元，在纽交所首次亮相即大涨11月6日 - ** 药物开发商Evommune的EVMN.N股票在纽约证交所首次上市时大涨26.1%。** EVMN 是自 9 月份以来第三家上市的著名美国生物技术公司，因为药物开发商的首次公开募股在长达数月的冻结后卷土重来。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL4T3WI26L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EVMN"],"gpt_icon":0},{"id":"2581015296","title":"美股異動 | 生物醫藥公司Evommune(EVMN.US)登陸美股市場 股價升逾15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581015296","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581015296?lang=zh_tw&edition=fundamental","pubTime":"2025-11-07 00:00","pubTimestamp":1762444800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Evommune(EVMN.US)登陆美股市场，截至发稿，该股涨超15%，报18.38美元，IPO价格为16美元。Evommune 是一家临床阶段的生物医药公司，其使命是通过创新疗法，治疗 “免疫介导的慢性炎症性疾病”。这类疾病包括慢性荨麻疹、特应性皮炎、其他与肥大细胞/炎症相关的病症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EVMN","161726","399441"],"gpt_icon":0},{"id":"2576361788","title":"慢性炎症性疾病生物科技公司Evommune(EVMN.US)IPO定價15-17美元/股 擬籌資1.5億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576361788","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576361788?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 15:54","pubTimestamp":1760946879,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注研发慢性炎症性疾病疗法的二期临床阶段生物科技公司Evommune于上周五公布了其首次公开募股的发行条款。公司计划通过发行940万股股票筹集1.5亿美元，发行价区间设定为15至17美元。若按发行价区间中值计算，Evommune的市值将达到5.43亿美元。该药物已启动2b期临床试验，预计于2026年下半年公布结果。由于美国政府持续停摆，Evommune未依赖美国证券交易委员会宣布其注册声明生效。公司预计于2025年11月3日当周确定最终发行价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EVMN","159837"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}